Emory University;Dana-Farber Cancer Institute Inc.
发明人:
Gordon Freeman,Kehmia Titanji,Rafi Ahmed,Rama Amara,Vijayakumar Velu
申请号：
BRPI0921321
公开号：
BRPI0921321A2
申请日:
2009.11.27
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.
